Check Cap (MBAI) Akcija Цена

Check Cap Цена

NASDAQ·ZATVORENO
3,03
​
Tržište je zatvoreno

Cena akcije Check Cap

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Check Cap poslovni model i analiza akcije

Check Cap Ltd je međunarodna biotehnološka kompanija specijalizovana za razvoj neinvazivnih dijagnostičkih tehnologija za rano otkrivanje raka debelog creva. Kompanija ima sedište u Izraelu i osnovana je 2004. godine.

Često postavljana pitanja o akciji Check Cap

The business model of Check Cap Ltd is focused on developing and commercializing an ingestible capsule system for colorectal cancer screenings. This innovative technology, known as the C-Scan, utilizes ultra-low dose X-ray technology to generate 3D images of the colon. By providing a non-invasive and patient-friendly alternative to traditional colonoscopies, Check Cap aims to increase the accessibility and early detection of colorectal cancer. This approach holds great potential in improving global healthcare outcomes and reducing healthcare costs associated with colorectal cancer screenings. As a leader in medical imaging technology, Check Cap Ltd is committed to driving advancements in the field of gastroenterology and revolutionizing cancer diagnostics.

Check Cap Ltd is primarily active in the healthcare industry, specifically in the field of medical diagnostics.

The main competitors of Check Cap Ltd in the market include companies such as Exact Sciences Corporation, Cerner Corporation, and Medtronic plc.

Check Cap Ltd is a pioneering medical technology company founded in 2004. The company focuses on the development of innovative capsule-based solutions for the medical imaging industry. Check Cap Ltd specializes in developing the C-Scan® system, a patient-friendly device designed to detect colorectal polyps and other gastrointestinal abnormalities. With cutting-edge imaging technology and a commitment to improving patient care, Check Cap Ltd has become a leading player in the medical imaging industry. Known for its dedication to innovation and its focus on improving diagnostic procedures, Check Cap Ltd continues to make significant advancements in the field of gastrointestinal imaging.

Check Cap Ltd has achieved several significant milestones in its journey. Some notable achievements include the successful completion of clinical trials for its C-Scan system, which is a revolutionary ingestible capsule for colorectal cancer screening. The company has also obtained CE Mark approval for the C-Scan system, allowing it to be marketed and sold in Europe. In addition, Check Cap Ltd has entered into partnerships and collaborations with renowned healthcare institutions and industry leaders, further enhancing its position in the market. These milestones highlight Check Cap Ltd's commitment to developing innovative solutions for early detection and prevention of colorectal cancer.

Check Cap Ltd is primarily present in Israel, the United States, and Europe.

Check Cap Ltd is committed to upholding strong values and a clear corporate philosophy. As a company specializing in medical diagnostics, Check Cap prioritizes integrity, innovation, and excellence in its operations. By developing cutting-edge technologies, Check Cap aims to revolutionize the field of screening and early detection of colorectal cancer. The company's core philosophy revolves around patient care, providing non-invasive solutions for effective diagnosis. Check Cap Ltd strives to foster an environment of trust, transparency, and social responsibility, driving its commitment to improving healthcare outcomes and enhancing patients' lives.

6 analitičara trenutno ocenjuje akciju Check Cap: 0 preporučuje kupovinu, 3 držanje i 3 prodaju. Za 2026 analitičari očekuju da Check Cap ostvari prihod 4,76 М USD i zaradu po akciji -0,16 USD.

Po trenutnom kursu akcija Check Cap kotira 2,70 EUR (3,03 USD).

Akcija Check Cap (MBAI) kotira na 3 berze, uključujući: NASDAQ (CHEK), Frankfurt (7CC.F), München (7CC.MU).

Check Cap Ltd is a research-based medical technology company based in Israel. It develops products for the prevention, diagnosis, and monitoring of gastroenterological diseases, with its core product being the C-Scan®. The C-Scan® is a non-invasive, capsule-based technology that allows for the scanning of the entire digestive tract to detect potential tumors or other abnormalities early on. It offers an alternative to traditional colonoscopies and improves diagnostic accuracy. The C-Scan® is easy to use, painless, and requires no prior preparation or cleaning of the colon. Check Cap also conducts clinical studies to develop and test medications for gastroenterological diseases and works on new technologies for better visualization of the digestive tract. Its business model combines research and development, clinical studies, product development, and partnerships with other companies and institutions. With its innovative technology, Check Cap has the potential to change the way gastroenterological diseases are diagnosed, treated, and monitored.

očekivana prihod od Check Cap je 4,76 М USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od Check Cap je -145.800,00 USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Check Cap je trenutno -18,47. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Check Cap.

Odnos cene i prihoda (KUV) za Check Cap je trenutno 0,57. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Check Cap.

Eulpool score kvaliteta za Check Cap je 2/10.

ISIN za Check Cap je IL0011336851. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Check Cap je A14QUF. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Check Cap je MBAI. Simbol tikera se koristi za trgovinu akcijama Check Cap na berzanskom tržištu.

Фер вредностTerminal
2,81 USD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Медицинска опрема и понуде
Број акција
Запослени
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт check-cap.com
Земља
Израел
Валута
USD
Јавна понуда
19. феб 2015.
ISIN
IL0011336851
CUSIP
M2361E203
SEDOL
BVTGHG0
Тржишна капитализација
22,05 М USDMicro Cap
Опсег од 52 недеље
AAQS
3 / 10
PEG
—
P/E однос
P/Ee 2026
-18,47
P/Ee 2027
—
P/S
P/Se
0,57
EV/EBIT
—
P/B однос
6,42
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
119,90 %
Zadnje ažurirano 16. окт 2026. 21:31

Check Cap Peer grupa

Check Cap Тикер

FRANKFURT · 7CC.FMINHEN · 7CC.MUNASDAQ · CHEK

Check Cap FIGI

CHEK:US · BBG0089RJVS4CHEK:UA · BBG0089RJVT3CHEK:UC · BBG0089RJVV0CHEK:UN · BBG0089RJVX8CHEK:UP · BBG0089RJVY7CHEK:UB · BBG0089RJW02CHEK:UM · BBG0089RJW20CHEK:UX · BBG0089RJW39CHEK:UR · BBG0089RJW48CHEK:UD · BBG0089RJW93CHEK:UF · BBG0089RJWD8CHEK:VY · BBG0089RJWF6

Sve ključne metrke i detaljne analize Check Cap u dubinskoj analizi

Naša analiza akcija za akciju Check Cap uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Check Cap. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: